Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 04, 2026
Why Is Fidelity National Information Services (FIS) Stock Down -10.07% Today?

Why Is Fidelity National Information Services (FIS) Stock Down -10.07% Today?

Key Takeaways

  • FIS shares plunged approximately 10.07% in intraday trading on Monday, falling to $40.27 from a prior close of $44.78.
  • The primary catalyst was a cut to full-year 2026 revenue and profit guidance, despite the company posting a slight earnings beat for the second quarter.
  • Q3 2026 guidance also came in below Wall Street consensus, exacerbating investor concerns about near-term growth momentum.
  • Macroeconomic headwinds including geopolitical tensions and trade policy uncertainty were cited as factors weighing on client technology spending.
  • Trading volume was sharply elevated, signaling strong conviction behind the sell-off.
  • Traders are now watching for analyst downgrades and any further commentary around the demand environment heading into the second half of 2026.

Opening Summary

Fidelity National Information Services, Inc. (FIS), a global provider of financial technology solutions spanning banking, capital markets, and payments processing, saw its stock tumble roughly 10.07% on Monday. Shares dropped to $40.27 in intraday trading, down sharply from Friday's closing price of $44.78. The sell-off was driven by the company's decision to lower its full-year 2026 revenue and adjusted earnings forecasts, overshadowing a modest second-quarter earnings beat. The revised guidance, coupled with third-quarter projections that fell short of analyst expectations, triggered a broad retreat from the stock as investors recalibrated growth assumptions for the Jacksonville, Florida-based firm.

Earnings Beat Overshadowed by Guidance Cut

FIS reported second-quarter 2026 adjusted earnings of $1.48 per share, edging past the consensus estimate of $1.47 per share. Revenue for the quarter came in at $3.38 billion, in line with analyst expectations. While the headline numbers were respectable, the market's focus immediately shifted to the company's forward outlook.

For the third quarter of 2026, FIS guided adjusted earnings to a range of $1.58 to $1.62 per share, noticeably below the Wall Street consensus of $1.65. Revenue guidance of $3.41 billion to $3.44 billion also trailed the expected $3.52 billion. Perhaps more concerning to investors was the downward revision to the full-year forecast: the company now expects adjusted earnings of $6.15 to $6.24 per share, down from a prior range of $6.22 to $6.32, and full-year revenue of $13.63 billion to $13.70 billion, reduced from the earlier outlook of $13.77 billion to $13.85 billion. The combination of a modest top-and-bottom-line beat paired with decidedly cautious guidance created a textbook sell-the-news reaction.

Macroeconomic Uncertainty Weighs on Client Spending

Management pointed to broader economic uncertainty as a key factor behind the tempered outlook. Geopolitical tensions linked to the Iran conflict, along with ongoing U.S. trade policy turbulence, have prompted financial institutions and retailers to exercise greater caution around technology spending. This hesitancy is directly impacting demand for certain banking and capital-markets products within FIS's portfolio. While CEO Stephanie Ferris noted that banks continue to invest in technology modernization and artificial intelligence initiatives — a structural tailwind for the company — the near-term spending caution appears to be outweighing those secular trends in the current quarter.

Market Context and Trading Activity

The sell-off in FIS was accompanied by heavy trading volume. Friday's session had already seen roughly 10.98 million shares change hands, well above the stock's average daily volume of approximately 6.6 million shares, and Monday's intraday activity suggested continued elevated participation. The magnitude of the decline pushed FIS well below key psychological and technical levels, with the stock now trading closer to its 52-week low of $37.42 than to its 52-week high of $79.32. The sharp move lower also reflected a broader reset in valuations within the fintech and payments processing space, where growth expectations have been under scrutiny amid the uncertain macro environment.

What Comes Next for FIS

Looking ahead, investors will be closely monitoring whether the demand softness flagged by management proves transitory or signals a more prolonged slowdown in financial technology spending. The company's next quarterly report will be critical in assessing whether the reduced guidance was sufficiently conservative or if further downward revisions may be necessary. Analyst reactions in the coming days — including potential ratings changes and price target adjustments — will likely shape near-term sentiment. Additionally, any developments on the geopolitical or trade policy fronts that alter the macroeconomic outlook could rapidly shift the calculus for FIS and its peers. On the positive side, the sustained investment by banks in AI and digital modernization provides a potential floor for long-term demand, even as near-term cyclical headwinds persist. The stock's dividend yield, now above 4%, may also attract income-oriented investors during this period of price weakness.

Trending AI Robots

For traders seeking systematic approaches to navigate volatile markets like the current fintech landscape, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of automated trading bots covering thousands of tickers across various strategies, timeframes, and performance metrics. However, only the strongest performers under prevailing market conditions are featured in the Trending AI Robots section. Each bot differs by trading style, holding period, and the symbols it trades, giving users the flexibility to align with strategies that match their risk tolerance and market outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FIS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


FIS in downward trend: price dove below 50-day moving average on September 04, 2026

FIS moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 45 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FIS as a result. In 54 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

The Moving Average Convergence Divergence Histogram (MACD) for FIS turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 25 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

The Aroon Indicator for FIS entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FIS's RSI Oscillator exited the oversold zone, 31 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where FIS advanced for three days, in 159 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.

FIS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.103) is normal, around the industry mean (7.462). P/E Ratio (5.270) is within average values for comparable stocks, (67.645). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (2.284). FIS's Dividend Yield (0.050) is considerably higher than the industry average of (0.010). P/S Ratio (1.571) is also within normal values, averaging (141.758).

The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 8.39B. The market cap for tickers in the group ranges from 100 to 207.9B. IBM holds the highest valuation in this group at 207.9B. The lowest valued company is ARSC at 100.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -1%. VEEA experienced the highest price growth at 100%, while SGRX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was 40%. For the same stocks of the Industry, the average monthly volume growth was 43% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 64
Price Growth Rating: 60
SMR Rating: 73
Profit Risk Rating: 93
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
FIS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of banking and payments technologies

Industry InformationTechnologyServices

Industry
Data Processing Services
Address
347 Riverside Avenue
Phone
+1 904 438-6000
Employees
44000
Web
https://www.fisglobal.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.